Premium
Xencor Inc (XNCR)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-04-10 | Mr. Bart Jan CornelissenSenior VP & CFO | -3,50k | 42,99k | Vente | 12,29 | 27,72k | -11,21% |
| 2026-03-05 | Ms. Celia E. EckertSenior VP, General Counsel & Corporate Secretary | -5,01k | 55,95k | Vente | 11,02 - 11,25 | 39,24k | -11,32% |
| 2026-03-05 | Dr. John R. DesjarlaisExec. VP of Research & Chief Scientific Officer | -6,62k | 73,88k | Vente | 11,02 - 11,25 | 212,12k | -3,03% |
| 2026-03-05 | Dr. Bassil I. DahiyatCo-Founder, CEO, President & Director | -21,48k | 240,02k | Vente | 11,02 - 11,25 | 357,68k | -5,66% |
| 2026-03-05 | Mr. Bart Jan CornelissenSenior VP & CFO | -2,52k | 28,30k | Vente | 11,25 | 17,13k | -12,81% |
| 2026-03-03 | Dr. John R. DesjarlaisExec. VP of Research & Chief Scientific Officer | -2,66k | 31,68k | Vente | 11,90 | 201,88k | -1,30% |
| 2026-03-03 | Dr. Bassil I. DahiyatCo-Founder, CEO, President & Director | -6,76k | 80,39k | Vente | 11,90 | 324,40k | -2,04% |
| 2026-03-03 | Ms. Celia E. EckertSenior VP, General Counsel & Corporate Secretary | -1,49k | 17,75k | Vente | 11,90 | 32,57k | -4,38% |
| 2026-01-23 | Dr. John R. DesjarlaisExec. VP of Research & Chief Scientific Officer | 5,32k | 66,58k | Derivative Exercise and Retained Stock | 12,51 | 198,29k | 2,76% |
| 2025-12-22 | Dr. Bassil I. DahiyatCo-Founder, CEO, President & Director | 10,62k | 132,91k | Derivative Exercise and Retained Stock | 12,51 | 313,65k | 3,51% |
| 2025-12-19 | Dr. Bassil I. DahiyatCo-Founder, CEO, President & Director | -114,38k | 366,01k | Derivative Exercise and Sale | 12,51 - 15,71 | 313,65k | - |
| 2025-12-22 | Dr. John R. DesjarlaisExec. VP of Research & Chief Scientific Officer | 6,31k | 78,95k | Derivative Exercise and Retained Stock | 12,51 | 192,97k | 3,38% |
| 2025-12-19 | Dr. John R. DesjarlaisExec. VP of Research & Chief Scientific Officer | -73,37k | 235,51k | Derivative Exercise and Sale | 12,51 - 15,72 | 192,97k | - |
| 2025-06-16 | Dr. Alan Bruce Montgomerylead Independent Director | -2,22k | 20,42k | Automatic Disposition | 9,22 | 6,93k | -24,23% |
| 2025-06-16 | Mr. Kurt A. GustafsonIndependent Director | -2,99k | 27,60k | Automatic Disposition | 9,22 | 6,50k | -31,54% |
| 2025-06-16 | Dr. Kevin C. GormanIndependent Director | -3,17k | 29,26k | Vente | 9,22 | 5,22k | -37,81% |
| 2025-06-16 | Dr. Ellen Gwen FeigalIndependent Director | -2,99k | 27,60k | Automatic Disposition | 9,22 | 5,50k | -35,25% |
| 2025-06-16 | Mr. Richard J. RanieriIndependent Director | -2,99k | 27,60k | Automatic Disposition | 9,22 | 5,50k | -35,25% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
